Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA May Change Opioid Labeling To Limit Dispensing By Indication

Executive Summary

Commissioner Gottlieb says FDA is looking to work with provider groups to set dosage based on indication; Patrick Kennedy is calling on CMS to provide reimbursement for opioid addiction treatment.

You may also be interested in...



Opioid Litigation: Court Asks US FDA To Attend Education Session

Judge overseeing multidistrict litigation convenes meeting with senior pharma executives, government plaintiffs and others to learn about supply-chain dynamics and other issues to resolve more than 200 suits.

Opioid Packaging Standards Could Emerge From Dosage Guidelines in Labeling

US FDA wants to work with practitioners to develop suggested prescribing standards, which could then be used to create packaging requirements.

Opioid Packaging Standards Could Emerge From Dosage Guidelines in Labeling

US FDA wants to work with practitioners to develop suggested prescribing standards, which could then be used to create packaging requirements.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS121546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel